151 related articles for article (PubMed ID: 37542770)
1. Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion.
Zhou N; Wu M; Yuan M; Wu H; Yu S; Gao X; Wang Y
Lung Cancer; 2023 Sep; 183():107289. PubMed ID: 37542770
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract][Full Text] [Related]
3. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
5. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
6. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract][Full Text] [Related]
7. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
8. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
Fang L; Ding G; Wang M; Ye Y; Yan X; Ding P; Wang J; Zhang Y
Medicine (Baltimore); 2022 Aug; 101(34):e30255. PubMed ID: 36042596
[TBL] [Abstract][Full Text] [Related]
9. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
Wang T; Du G; Niu M; Liu R
BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
[TBL] [Abstract][Full Text] [Related]
10. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
Lin J; Wang W; Lin J; Chen R; Cao Y
J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
[TBL] [Abstract][Full Text] [Related]
11. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature.
Walls M; Walls GM; James JA; Crawford KT; Abdulkhalek H; Lynch TB; Peace AJ; McManus TE; Evans OR
BMC Pulm Med; 2020 Aug; 20(1):209. PubMed ID: 32762670
[TBL] [Abstract][Full Text] [Related]
13. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report.
Chen L; Chu D; Li W; Zhang H
Anticancer Drugs; 2024 Jan; 35(1):97-100. PubMed ID: 37450292
[TBL] [Abstract][Full Text] [Related]
15. A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.
Cheng W; Qian C; Zhang H; Meng Q; Yin JC; Fang S
Anticancer Drugs; 2022 Nov; 33(10):1182-1185. PubMed ID: 35946559
[TBL] [Abstract][Full Text] [Related]
16. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
Liu D; Xu X; Wen J; Zhang C; Fan M
Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
[TBL] [Abstract][Full Text] [Related]
17. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
[TBL] [Abstract][Full Text] [Related]
18. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
20. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Liu L; Hou F; Liu Y; Li W; Zhang H
J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
